NMTCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
NEUROONE MEDICAL TECHNOLOGIES Corp
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.00+0.04 (+4.01%)
Close on Oct 19, 2026
- Market cap
- $8.74M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2009 to 2025
Gross margin
56.5%
Operating margin
-46.5%
Net margin
-39.6%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +163.5% | +276.0% | – | – | |
| Gross profit | +376.2% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2014 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 110.4% | – | -91.3% | |
| Return on assets | -9929.9% | – | -44.6% | |
| Current ratio | 0.01 | 1.76 | 4.44 | |
| Debt to equity | – | 0.61 | – | |
| Net debt to EBITDA | – | 0.57× | – | |
| Interest coverage | -108.8× | – | – | |
| Inventory turnover | – | – | 1.6× | |
| Capex to revenue | – | – | 0.9% | |
| Diluted shares | 0M | 1M | 7M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Neuroone Medical Technologies generated $42.86M from operations and spent $928.36K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$42.86M
Used
$928.36K
Capital expenditure$928.36K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-39.6%
×Asset turnover1.13×
×Equity multiplier2.05×
=Return on equity, FY2025-91.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -39.6% | 1.13× | 2.05× | -91.3% |
| FY2024 | -356.7% | 0.51× | 1.90× | -348.4% |
| FY2023 | -607.4% | 0.19× | 1.32× | -149.6% |
| FY2022 | -5842.0% | 0.02× | 1.28× | -123.8% |
| FY2021 | -5584.3% | 0.03× | 1.47× | -230.8% |
| FY2014 | -4688.7% | 2.12× | -0.01× | 110.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$3.61M
- Cash generatingOperating cash flow above zero-$2.84M
- Return on assets improvedROA up on the prior year-152.1% → -67.1%
- Earnings backed by cashOperating cash flow above net income-$2.84M vs -$3.61M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.09 → 4.44
- No dilutionShare count did not rise4M → 7M
- Gross margin improvedGross margin up on the prior year31.27% → 56.51%
- More efficientAsset turnover rose0.43 → 1.69